Your browser doesn't support javascript.
loading
[Active and refractory ulcerative proctitis: an update]. / Proctitis ulcerosa activa y refractaria: Una puesta al día.
Caselli M, Gino; Pinedo M, George; Zúñiga D, Alvaro; Alvarez L, Manuel.
Afiliação
  • Caselli M G; Unidad de Cirugía Colorrectal, Hospital Clínico, Pontificia Universidad Católica de ChileChile.
Rev Med Chil ; 138(1): 109-16, 2010 Jan.
Article em Es | MEDLINE | ID: mdl-20361160
ABSTRACT
Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology that affects a variable length of the colon, starting from the rectum. When the disease is confined to the rectum is called ulcerative proctitis (UP). Several studies have unsuccessfully attempted to determine the factors that determine the extent of involvement. The goals of therapy in UP are to induce and maintain remission of symptoms and disease. Topical treatment with 5-aminosalicylates (5-ASA) is the treatment of choice to induce remission. In the maintenance phase, long-term follow up studies suggest that treatment with 5-ASA is better than placebo, to maintain the disease inactive. For those patients that do not respond to treatment with topical 5-ASA or have a moderate to severe disease, there are additional therapies such as oral 5-ASA, topical or systemic corticosteroids, immunomodulators, biological therapies (Infliximab) and cyclosporine. Surgery is seldom needed.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proctite / Colite Ulcerativa / Anti-Inflamatórios Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Humans Idioma: Es Revista: Rev Med Chil Ano de publicação: 2010 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proctite / Colite Ulcerativa / Anti-Inflamatórios Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Humans Idioma: Es Revista: Rev Med Chil Ano de publicação: 2010 Tipo de documento: Article